John D. Ulm

Array ( [id] => 14594233 [patent_doc_number] => 10350293 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-16 [patent_title] => Compositions and methods for treating symptoms associated with multiple sclerosis [patent_app_type] => utility [patent_app_number] => 15/676405 [patent_app_country] => US [patent_app_date] => 2017-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8911 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15676405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14198977 [patent_doc_number] => 10266582 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-23 [patent_title] => GPR156 variants and uses thereof [patent_app_type] => utility [patent_app_number] => 15/662689 [patent_app_country] => US [patent_app_date] => 2017-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 32554 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15662689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15355565 [patent_doc_number] => 10526383 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-07 [patent_title] => Ghrelin splice variant for treating neuronal damage, neurodegenerative disease, parkinsons disease, alzheimers disease, and/or depression [patent_app_type] => utility [patent_app_number] => 15/663039 [patent_app_country] => US [patent_app_date] => 2017-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 30124 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15663039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12138220 [patent_doc_number] => 20180016303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'BK CHANNEL-MODULATING PEPTIDES AND THEIR USE' [patent_app_type] => utility [patent_app_number] => 15/650375 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 28232 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435481 [patent_doc_number] => 20200031924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders [patent_app_type] => utility [patent_app_number] => 16/316428 [patent_app_country] => US [patent_app_date] => 2017-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76545 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16316428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12150024 [patent_doc_number] => 20180021288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'Neuroprotection in Demyelinating Diseases' [patent_app_type] => utility [patent_app_number] => 15/644029 [patent_app_country] => US [patent_app_date] => 2017-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 14445 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15644029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992468 [patent_doc_number] => 20170296624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'GLA DOMAINS AS TARGETING AGENTS' [patent_app_type] => utility [patent_app_number] => 15/631937 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 18403 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15631937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12584976 [patent_doc_number] => 20180086821 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => HUMAN IgM ANTIBODIES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF PARTICULARLY IN THE CENTRAL NERVOUS SYSTEM [patent_app_type] => utility [patent_app_number] => 15/629123 [patent_app_country] => US [patent_app_date] => 2017-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15629123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13714487 [patent_doc_number] => 20170368198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => OPTIMIZED MINI-DYSTROPHIN GENES AND EXPRESSION CASSETTES AND THEIR USE [patent_app_type] => utility [patent_app_number] => 15/628268 [patent_app_country] => US [patent_app_date] => 2017-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49976 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15628268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14198987 [patent_doc_number] => 10266587 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-23 [patent_title] => Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers [patent_app_type] => utility [patent_app_number] => 15/621105 [patent_app_country] => US [patent_app_date] => 2017-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 70 [patent_figures_cnt] => 70 [patent_no_of_words] => 50498 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15621105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14743839 [patent_doc_number] => 20190255093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES [patent_app_type] => utility [patent_app_number] => 16/308007 [patent_app_country] => US [patent_app_date] => 2017-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33993 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969894 [patent_doc_number] => 20170274046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEUROLOGICAL DISEASE' [patent_app_type] => utility [patent_app_number] => 15/617968 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 53109 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15617968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969883 [patent_doc_number] => 20170274037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'PEPTIDES FOR SUPPRESSING INFLAMMATION' [patent_app_type] => utility [patent_app_number] => 15/612641 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 13483 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15612641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11964910 [patent_doc_number] => 20170269063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'FELINE BITTER TASTE RECEPTORS AND METHODS' [patent_app_type] => utility [patent_app_number] => 15/601492 [patent_app_country] => US [patent_app_date] => 2017-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 20036 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15601492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092571 [patent_doc_number] => 20170349664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS' [patent_app_type] => utility [patent_app_number] => 15/597021 [patent_app_country] => US [patent_app_date] => 2017-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 44247 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15597021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12584928 [patent_doc_number] => 20180086805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => proNGF mutants and uses thereof for the preparation of NGF mutants [patent_app_type] => utility [patent_app_number] => 15/593527 [patent_app_country] => US [patent_app_date] => 2017-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17574 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15593527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13278449 [patent_doc_number] => 10150796 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-11 [patent_title] => Peptide inhibitors of sodium channels [patent_app_type] => utility [patent_app_number] => 15/591684 [patent_app_country] => US [patent_app_date] => 2017-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 32 [patent_no_of_words] => 12210 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15591684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11929782 [patent_doc_number] => 09796768 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-24 [patent_title] => 'Peptide inhibitors of sodium channels' [patent_app_type] => utility [patent_app_number] => 15/494210 [patent_app_country] => US [patent_app_date] => 2017-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 32 [patent_no_of_words] => 13009 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15494210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11995453 [patent_doc_number] => 20170299609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH SK CHANNEL ACTIVATORS' [patent_app_type] => utility [patent_app_number] => 15/490094 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5774 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15490094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219201 [patent_doc_number] => 20180057561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'PD-L1 AND PD-L2-BASED FUSION PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/487539 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22871 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15487539 [rel_patent_id] =>[rel_patent_doc_number] =>)